- Home
- NRO vs CRVO Comparison
NRO vs CRVO Comparison
Compare NRO & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CRVO
- Stock Information
- Founded
- NRO 2003
- CRVO 2001
- Country
- NRO United States
- CRVO United States
- Employees
- NRO N/A
- CRVO N/A
- Industry
- NRO Finance/Investors Services
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- CRVO Health Care
- Exchange
- NRO Nasdaq
- CRVO Nasdaq
- Market Cap
- NRO 156.7M
- CRVO 67.4M
- IPO Year
- NRO N/A
- CRVO N/A
- Fundamental
- Price
- NRO $3.24
- CRVO $6.96
- Analyst Decision
- NRO
- CRVO Strong Buy
- Analyst Count
- NRO 0
- CRVO 7
- Target Price
- NRO N/A
- CRVO $19.33
- AVG Volume (30 Days)
- NRO 239.4K
- CRVO 161.9K
- Earning Date
- NRO 01-01-0001
- CRVO 08-08-2025
- Dividend Yield
- NRO 11.41%
- CRVO N/A
- EPS Growth
- NRO N/A
- CRVO N/A
- EPS
- NRO N/A
- CRVO N/A
- Revenue
- NRO N/A
- CRVO $9,308,215.00
- Revenue This Year
- NRO N/A
- CRVO N/A
- Revenue Next Year
- NRO N/A
- CRVO N/A
- P/E Ratio
- NRO N/A
- CRVO N/A
- Revenue Growth
- NRO N/A
- CRVO 15.14
- 52 Week Low
- NRO $2.51
- CRVO $1.80
- 52 Week High
- NRO $3.45
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- NRO 52.08
- CRVO 51.63
- Support Level
- NRO $3.19
- CRVO $5.45
- Resistance Level
- NRO $3.27
- CRVO $7.55
- Average True Range (ATR)
- NRO 0.04
- CRVO 0.59
- MACD
- NRO 0.00
- CRVO 0.14
- Stochastic Oscillator
- NRO 65.00
- CRVO 75.71
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.